aluates Reports

$ 0.0

Automative

Global Castrate Resistant Prostate Cancer Therapeutics Market Research Report 2026

Published Date: 2026-04-23

Report Code: QYRE-Auto-1F13309

Global Castrate Resistant Prostate Cancer Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Castrate Resistant Prostate Cancer Therapeutics Market Research Report 2026

Code: QYRE-Auto-1F13309

Report

2026-04-23

Pages:106

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Johnson & Johnson

Bayer

Jiangsu Hengrui Pharmaceuticals

CTTQ

Sanofi

HANSOH

Clovis Oncology

Zhendong Pharmaceutical

Pfizer/Astellas (Xtandi)

AstraZeneca/Merck (Lynparza)

Johnson & Johnson

Castrate Resistant Prostate Cancer Therapeutics Market Size

The global Castrate Resistant Prostate Cancer Therapeutics market was valued at US$ 20700 million in 2025 and is anticipated to reach US$ 43130 million by 2032, at a CAGR of 11.2% from 2026 to 2032.

Castrate Resistant Prostate Cancer Therapeutics Market

Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. Also called CRPC.

The treatment of castration-resistant prostate cancer is to use various methods to treat the recurrence and metastasis of cancer cells or to control hormones.

Global key players of castrate resistant prostate cancer therapeutics include Pfizer, Johnson & Johnson, AstraZeneca, Bayer, Jiangsu Hengrui Pharmaceuticals etc. The top five players hold a share over 70%. North America is the largest market, has a share over 40%, followed by Europe, and Asia-Pacific, with share 28% and 22%, separately.

This report delivers a comprehensive overview of the global Castrate Resistant Prostate Cancer Therapeutics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Castrate Resistant Prostate Cancer Therapeutics. The Castrate Resistant Prostate Cancer Therapeutics market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Castrate Resistant Prostate Cancer Therapeutics market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Castrate Resistant Prostate Cancer Therapeutics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Castrate Resistant Prostate Cancer Therapeutics Market Report

Report Metric	Details
Report Name	Castrate Resistant Prostate Cancer Therapeutics Market
Accounted market size in 2025	US$ 20700 million
Forecasted market size in 2032	US$ 43130 million
CAGR	11.2%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Hormonal Therapy Chemotherapy Others
Segment by Application	Hospital Specialty Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer/Astellas (Xtandi), Johnson & Johnson, AstraZeneca/Merck (Lynparza), Bayer, Jiangsu Hengrui Pharmaceuticals, CTTQ, Sanofi, Hansoh, Clovis Oncology, Zhendong Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Castrate Resistant Prostate Cancer Therapeutics companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Castrate Resistant Prostate Cancer Therapeutics Market growing?

Ans: The Castrate Resistant Prostate Cancer Therapeutics Market witnessing a CAGR of 11.2% during the forecast period 2026-2032.

What is the Castrate Resistant Prostate Cancer Therapeutics Market size in 2032?

Ans: The Castrate Resistant Prostate Cancer Therapeutics Market size in 2032 will be US$ 43130 million.

What is the market share of major companies in Castrate Resistant Prostate Cancer Therapeutics Market?

Ans: The top five players hold a share over 70%.

What is the Castrate Resistant Prostate Cancer Therapeutics Market share by region?

Ans: North America is the largest market, has a share over 40%, followed by Europe, and Asia-Pacific, with share 28% and 22%, separately.

Who are the main players in the Castrate Resistant Prostate Cancer Therapeutics Market report?

Ans: The main players in the Castrate Resistant Prostate Cancer Therapeutics Market are Pfizer/Astellas (Xtandi), Johnson & Johnson, AstraZeneca/Merck (Lynparza), Bayer, Jiangsu Hengrui Pharmaceuticals, CTTQ, Sanofi, Hansoh, Clovis Oncology, Zhendong Pharmaceutical

What are the Application segmentation covered in the Castrate Resistant Prostate Cancer Therapeutics Market report?

Ans: The Applications covered in the Castrate Resistant Prostate Cancer Therapeutics Market report are Hospital, Specialty Clinic, Others

What are the Type segmentation covered in the Castrate Resistant Prostate Cancer Therapeutics Market report?

Ans: The Types covered in the Castrate Resistant Prostate Cancer Therapeutics Market report are Hormonal Therapy, Chemotherapy, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Hormonal Therapy

1.2.3 Chemotherapy

1.2.4 Others

1.3 Market by Application

1.3.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Hospital

1.3.3 Specialty Clinic

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Perspective (2021–2032)

2.2 Global Castrate Resistant Prostate Cancer Therapeutics Growth Trends by Region

2.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Region (2021–2026)

2.2.3 Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (2027–2032)

2.3 Castrate Resistant Prostate Cancer Therapeutics Market Dynamics

2.3.1 Castrate Resistant Prostate Cancer Therapeutics Industry Trends

2.3.2 Castrate Resistant Prostate Cancer Therapeutics Market Drivers

2.3.3 Castrate Resistant Prostate Cancer Therapeutics Market Challenges

2.3.4 Castrate Resistant Prostate Cancer Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue

3.1.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue (2021–2026)

3.1.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Players (2021–2026)

3.2 Global Top Castrate Resistant Prostate Cancer Therapeutics Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Castrate Resistant Prostate Cancer Therapeutics Revenue

3.4 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio

3.4.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2025

3.5 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics Head Offices and Areas Served

3.6 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Products and Applications

3.7 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Type

4.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Type (2021–2026)

4.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2027–2032)

5 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Application

5.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Application (2021–2026)

5.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size (2021–2032)

6.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2021–2026)

6.4 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size (2021–2032)

7.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2021–2026)

7.4 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size (2021–2032)

8.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2021–2026)

8.4 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size (2021–2032)

9.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2021–2026)

9.4 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size (2021–2032)

10.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2021–2026)

10.4 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer/Astellas (Xtandi)

11.1.1 Pfizer/Astellas (Xtandi) Company Details

11.1.2 Pfizer/Astellas (Xtandi) Business Overview

11.1.3 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Introduction

11.1.4 Pfizer/Astellas (Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

11.1.5 Pfizer/Astellas (Xtandi) Recent Development

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Company Details

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Introduction

11.2.4 Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

11.2.5 Johnson & Johnson Recent Development

11.3 AstraZeneca/Merck (Lynparza)

11.3.1 AstraZeneca/Merck (Lynparza) Company Details

11.3.2 AstraZeneca/Merck (Lynparza) Business Overview

11.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Introduction

11.3.4 AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

11.3.5 AstraZeneca/Merck (Lynparza) Recent Development

11.4 Bayer

11.4.1 Bayer Company Details

11.4.2 Bayer Business Overview

11.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Introduction

11.4.4 Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

11.4.5 Bayer Recent Development

11.5 Jiangsu Hengrui Pharmaceuticals

11.5.1 Jiangsu Hengrui Pharmaceuticals Company Details

11.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview

11.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Introduction

11.5.4 Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

11.5.5 Jiangsu Hengrui Pharmaceuticals Recent Development

11.6 CTTQ

11.6.1 CTTQ Company Details

11.6.2 CTTQ Business Overview

11.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Introduction

11.6.4 CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

11.6.5 CTTQ Recent Development

11.7 Sanofi

11.7.1 Sanofi Company Details

11.7.2 Sanofi Business Overview

11.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Introduction

11.7.4 Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

11.7.5 Sanofi Recent Development

11.8 Hansoh

11.8.1 Hansoh Company Details

11.8.2 Hansoh Business Overview

11.8.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Introduction

11.8.4 Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

11.8.5 Hansoh Recent Development

11.9 Clovis Oncology

11.9.1 Clovis Oncology Company Details

11.9.2 Clovis Oncology Business Overview

11.9.3 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Introduction

11.9.4 Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

11.9.5 Clovis Oncology Recent Development

11.10 Zhendong Pharmaceutical

11.10.1 Zhendong Pharmaceutical Company Details

11.10.2 Zhendong Pharmaceutical Business Overview

11.10.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Introduction

11.10.4 Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

11.10.5 Zhendong Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Johnson & Johnson

Bayer

Jiangsu Hengrui Pharmaceuticals

CTTQ

Sanofi

HANSOH

Clovis Oncology

Zhendong Pharmaceutical

Pfizer/Astellas (Xtandi)

AstraZeneca/Merck (Lynparza)

Johnson & Johnson

List of Tables

Table 1. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Hormonal Therapy

Table 3. Key Players of Chemotherapy

Table 4. Key Players of Others

Table 5. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (US$ Million), 2021–2026

Table 8. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2021–2026)

Table 9. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (US$ Million), 2027–2032

Table 10. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2027–2032)

Table 11. Castrate Resistant Prostate Cancer Therapeutics Market Trends

Table 12. Castrate Resistant Prostate Cancer Therapeutics Market Drivers

Table 13. Castrate Resistant Prostate Cancer Therapeutics Market Challenges

Table 14. Castrate Resistant Prostate Cancer Therapeutics Market Restraints

Table 15. Global Castrate Resistant Prostate Cancer Therapeutics Revenue by Players (US$ Million), 2021–2026

Table 16. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players (2021–2026)

Table 17. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Tier (Tier 1, Tier 2, and Tier 3), based on Castrate Resistant Prostate Cancer Therapeutics Revenue, 2025

Table 18. Ranking of Global Top Castrate Resistant Prostate Cancer Therapeutics Companies by Revenue (US$ Million) in 2025

Table 19. Global 5 Largest Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue (CR5 and HHI), 2021–2026

Table 20. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Headquarters and Area Served

Table 21. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Products and Applications

Table 22. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Date of General Availability (GA)

Table 23. Mergers and Acquisitions, Expansion Plans

Table 24. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (US$ Million), 2021–2026

Table 25. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2021–2026)

Table 26. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (US$ Million), 2027–2032

Table 27. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2027–2032)

Table 28. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (US$ Million), 2021–2026

Table 29. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2021–2026)

Table 30. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (US$ Million), 2027–2032

Table 31. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2027–2032)

Table 32. North America Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 33. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 34. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 35. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 36. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 37. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 38. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 39. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (US$ Million), 2021–2026

Table 40. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (US$ Million), 2027–2032

Table 41. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 43. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 44. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 46. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 47. Pfizer/Astellas (Xtandi) Company Details

Table 48. Pfizer/Astellas (Xtandi) Business Overview

Table 49. Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Product

Table 50. Pfizer/Astellas (Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (US$ Million), 2021–2026

Table 51. Pfizer/Astellas (Xtandi) Recent Development

Table 52. Johnson & Johnson Company Details

Table 53. Johnson & Johnson Business Overview

Table 54. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Product

Table 55. Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (US$ Million), 2021–2026

Table 56. Johnson & Johnson Recent Development

Table 57. AstraZeneca/Merck (Lynparza) Company Details

Table 58. AstraZeneca/Merck (Lynparza) Business Overview

Table 59. AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Product

Table 60. AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (US$ Million), 2021–2026

Table 61. AstraZeneca/Merck (Lynparza) Recent Development

Table 62. Bayer Company Details

Table 63. Bayer Business Overview

Table 64. Bayer Castrate Resistant Prostate Cancer Therapeutics Product

Table 65. Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (US$ Million), 2021–2026

Table 66. Bayer Recent Development

Table 67. Jiangsu Hengrui Pharmaceuticals Company Details

Table 68. Jiangsu Hengrui Pharmaceuticals Business Overview

Table 69. Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Product

Table 70. Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (US$ Million), 2021–2026

Table 71. Jiangsu Hengrui Pharmaceuticals Recent Development

Table 72. CTTQ Company Details

Table 73. CTTQ Business Overview

Table 74. CTTQ Castrate Resistant Prostate Cancer Therapeutics Product

Table 75. CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (US$ Million), 2021–2026

Table 76. CTTQ Recent Development

Table 77. Sanofi Company Details

Table 78. Sanofi Business Overview

Table 79. Sanofi Castrate Resistant Prostate Cancer Therapeutics Product

Table 80. Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (US$ Million), 2021–2026

Table 81. Sanofi Recent Development

Table 82. Hansoh Company Details

Table 83. Hansoh Business Overview

Table 84. Hansoh Castrate Resistant Prostate Cancer Therapeutics Product

Table 85. Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (US$ Million), 2021–2026

Table 86. Hansoh Recent Development

Table 87. Clovis Oncology Company Details

Table 88. Clovis Oncology Business Overview

Table 89. Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Product

Table 90. Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (US$ Million), 2021–2026

Table 91. Clovis Oncology Recent Development

Table 92. Zhendong Pharmaceutical Company Details

Table 93. Zhendong Pharmaceutical Business Overview

Table 94. Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Product

Table 95. Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (US$ Million), 2021–2026

Table 96. Zhendong Pharmaceutical Recent Development

Table 97. Research Programs/Design for This Report

Table 98. Key Data Information from Secondary Sources

Table 99. Key Data Information from Primary Sources

Table 100. Authors List of This Report

List of Figures

Figure 1. Castrate Resistant Prostate Cancer Therapeutics Picture

Figure 2. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Type: 2025 vs 2032

Figure 4. Hormonal Therapy Features

Figure 5. Chemotherapy Features

Figure 6. Others Features

Figure 7. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (US$ Million), 2021–2032

Figure 8. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Application: 2025 vs 2032

Figure 9. Hospital Case Studies

Figure 10. Specialty Clinic Case Studies

Figure 11. Others Case Studies

Figure 12. Castrate Resistant Prostate Cancer Therapeutics Report Years Considered

Figure 13. Global Castrate Resistant Prostate Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 14. Global Castrate Resistant Prostate Cancer Therapeutics Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 15. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region: 2025 vs 2032

Figure 16. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players in 2025

Figure 17. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2025

Figure 19. North America Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 20. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2021–2032)

Figure 21. United States Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Canada Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2021–2032)

Figure 25. Germany Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. France Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. U.K. Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Italy Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Russia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Ireland Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2021–2032)

Figure 33. China Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Japan Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. South Korea Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. India Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Australia & New Zealand Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2021–2032)

Figure 41. Mexico Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Brazil Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2021–2032)

Figure 45. Israel Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Saudi Arabia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. UAE Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Pfizer/Astellas (Xtandi) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

Figure 49. Johnson & Johnson Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

Figure 50. AstraZeneca/Merck (Lynparza) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

Figure 51. Bayer Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

Figure 52. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

Figure 53. CTTQ Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

Figure 54. Sanofi Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

Figure 55. Hansoh Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

Figure 56. Clovis Oncology Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

Figure 57. Zhendong Pharmaceutical Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2021–2026)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Castrate resistant Prostate Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Castration Resistant Prostate Cancer CRPC HRPCA Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Castration Resistant Prostate Cancer Treatment Market Research Report 2024

Hormone Refractory Prostate Cancer HRPCA Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hormone Sensitive Prostate Cancer Drugs Market Research Report 2024

Global Prostate Cancer Medicine Market Insights Forecast to 2030

Prostate Cancer Hormone Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Prostate Cancer Diagnostics and Treatment Market Research Report 2025

Prostate Cancer PARP Inhibitor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Prostate Cancer Market Insights Forecast to 2030

Global Colorectal Cancer Therapeutics Market Research Report 2024

Global Metastatic Prostate Cancer Treatment Market Research Report 2024

Global Prostate Cancer Devices Market Research Report 2025

Global Cancer Hormone Therapy Drugs Market Insights Forecast to 2030

Global Circulating Tumor Cells Market Research Report 2025

Global Urological Cancer Therapeutics Drugs Market Research Report 2024

Global Advanced Prostate Cancer Drug Market Research Report 2025

Prostate Cancer Therapeutics Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hormone Refractory Breast Cancer Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions